The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
出版年份 2022 全文链接
标题
The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
作者
关键词
-
出版物
Frontiers in Immunology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-10-27
DOI
10.3389/fimmu.2022.1045957
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Overexpression of CAPG Is Associated with Poor Prognosis and Immunosuppressive Cell Infiltration in Ovarian Cancer
- (2022) Senwei Jiang et al. DISEASE MARKERS
- CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
- (2022) Stefanie Seitz et al. BRITISH JOURNAL OF CANCER
- Novel insights into the interaction between N6-methyladenosine modification and circular RNA
- (2022) Tao Xu et al. Molecular Therapy-Nucleic Acids
- Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observational study
- (2022) Fumihiro Shoji et al. BMJ Open
- Identification of NAD+ Metabolism-Derived Gene Signatures in Ovarian Cancer Prognosis and Immunotherapy
- (2022) Liang Lin et al. Frontiers in Genetics
- Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
- (2022) Rachel E Sanborn et al. Journal for ImmunoTherapy of Cancer
- Gene signature of m6A-related targets to predict prognosis and immunotherapy response in ovarian cancer
- (2022) Wei Tan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer
- (2021) Moran Yang et al. Journal for ImmunoTherapy of Cancer
- Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
- (2021) Julianne D. Twomey et al. AAPS Journal
- Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer
- (2021) MAX R. CLEVERS et al. ANTICANCER RESEARCH
- Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies
- (2021) Marta Trüb et al. Frontiers in Immunology
- Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma
- (2021) Zhiwen Shi et al. Clinical and Translational Medicine
- ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer
- (2021) Yuka Kuroda et al. GYNECOLOGIC ONCOLOGY
- Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
- (2021) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
- (2021) Christine S. Walsh et al. PLoS One
- Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
- (2021) John B Liao et al. Journal for ImmunoTherapy of Cancer
- The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments
- (2021) Daniel Di Capua et al. Cancers
- Landscape of Immune Microenvironment in Epithelial Ovarian Cancer and Establishing Risk Model by Machine Learning
- (2021) Shi-yi Liu et al. Journal of Oncology
- Identification of a Gene Set Correlated With Immune Status in Ovarian Cancer by Transcriptome-Wide Data Mining
- (2021) Lili Fan et al. Frontiers in Molecular Biosciences
- Biomarkers of immunotherapy response in breast cancer beyond PD-L1
- (2021) Nuria Chic et al. BREAST CANCER RESEARCH AND TREATMENT
- Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
- (2021) Diego Chowell et al. NATURE BIOTECHNOLOGY
- Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer
- (2021) Fangfang Xu et al. Frontiers in Immunology
- Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
- (2021) Jinzhu Mao et al. Journal for ImmunoTherapy of Cancer
- Immune Cell Infiltration Landscape of Ovarian Cancer to Identify Prognosis and Immunotherapy-Related Genes to Aid Immunotherapy
- (2021) Xiushen Li et al. Frontiers in Cell and Developmental Biology
- High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition
- (2021) Ying Ni et al. npj Precision Oncology
- Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
- (2020) Shin Nishio et al. CANCER SCIENCE
- A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.
- (2020) Nehal J. Lakhani et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
- (2020) Erika J Lampert et al. CLINICAL CANCER RESEARCH
- Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.
- (2020) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
- (2020) Dmitriy Zamarin et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
- (2020) Anniina Färkkilä et al. Nature Communications
- Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
- (2020) Elizabeth K. Lee et al. GYNECOLOGIC ONCOLOGY
- Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy
- (2020) Julia L. Boland et al. GYNECOLOGIC ONCOLOGY
- Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer
- (2020) Fangran Liu et al. CANCER BIOLOGY & THERAPY
- Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer
- (2020) Emese Zsiros et al. JAMA Oncology
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Are Integrins Still Practicable Targets for Anti-Cancer Therapy?
- (2019) Alday-Parejo et al. Cancers
- Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer
- (2019) Sally Temraz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
- (2019) Joyce F. Liu et al. JAMA Oncology
- PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients
- (2018) Min Ren et al. HISTOPATHOLOGY
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.
- (2018) Rachel E. Sanborn et al. JOURNAL OF CLINICAL ONCOLOGY
- Current advancement on diagnosis of ovarian cancer using biosensing of CA 125 biomarker: Analytical approaches
- (2018) Nasrin Razmi et al. TRAC-TRENDS IN ANALYTICAL CHEMISTRY
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Tumor infiltrating lymphocytes in ovarian cancer
- (2015) Phillip P Santoiemma et al. CANCER BIOLOGY & THERAPY
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis
- (2013) Kosuke Tanegashima et al. FEBS LETTERS
- Integrins and metastasis
- (2013) Kirat Kumar Ganguly et al. Cell Adhesion & Migration
- Heterotrimeric G-proteins: a short history
- (2006) Graeme Milligan et al. BRITISH JOURNAL OF PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started